Analytical Cytometry Core Shared Resource ABSTRACT To advance our understanding of cancer etiology and to develop improved therapeutic approaches, it is critical for researchers to have the ability to routinely analyze and isolate discrete cell types from complex heterogeneous populations. The Analytical Cytometry Core (ACC) fulfills this vital function for CC members by providing services to define and isolate discrete immune system cells and cancer cells based on cell surface markers, to quantify and isolate cells that express fluorescent markers, and to examine discrete cell growth states. The ACC provides flow cytometry analysis and sorting instrumentation (ten analyzers, four sorters) to support the research goals of the City of Hope Comprehensive Cancer Center (COHCCC). The ACC maintains several analysis instruments (BC Gallios, BC CyAn, BD C6, and two BD Fortessas) that enable varying degrees of parameter detection in the Furth building on the COH main campus. These instruments can be operated either by researchers or by core staff. A small particle analyzer (e.g., exosome and nanoparticle; NanoSight NS300) is also available at this location. Additional analyzers are available throughout the main campus and the City of Hope Biomedical Research Center (BC Gallios, two BD C6, BD Fortessa, and BD Fortessa X-20). Three high-parameter cell sorting instruments (BD Aria sorters), located on the main campus and the City of Hope Biomedical Research Center, are maintained and operated by core staff. An additional simple cell sorter (Bio- Rad S3), located on the main campus, is available for operation by individual researchers. Several additional instruments are on order with scheduled delivery in July 2017: a BD Fortessa X-20, a BD Aria Fusion sorter, and a state-of-the-art high-dimensional cytometer (BD FACSymphony). The core is directed by Dr. Jeremy Stark, a Professor in the Department of Cancer Genetics and Epigenetics, and supported by highly qualified staff that maintain and operate the equipment while also providing training to COHCCC researchers who wish to operate ACC instruments independently. Trained and authorized users have 24/7 access to the instrumentation, and core staff schedules are staggered to allow for an extended workday for core-assisted operation. Oversight is provided by an interdisciplinary faculty Advisory Committee, and user feedback through an annual survey. Over the past five years, the ACC was used by 142 unique investigators, including 94 CC members. Of the 94 CC members, 79 (84%) had peer-reviewed funding. Usage included members from all five Programs. Thus, the ACC provides accessible, cost-effective, and high quality flow cytometry services to support the research of the COHCCC.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2018) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs 41:506-512

Showing the most recent 10 out of 1396 publications